TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Investigators' Global Assessment score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients pre-screened that were potentially eligible for study participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of approached patients that agreed to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportions of patients discontinuing prematurely from study treatment for any reason
Endpoint domain: Adverse events/effects
Primary endpoint: Counts of Faecalibacterium prausnitzii in faecal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: socket width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alveolar height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH) vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fullerton Advanced Balance Scale (FAB-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enrolment consent rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: protocol adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Children's Memory Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in overactive bladder symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in health related quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With a Metabolic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With a Toxic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of [14C]bendamustine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events assessed using CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Level of expression of the T regulator over total lymphocytes count ratio in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of expression of the T regulator over total lymphocytes count ratio into the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma concentration of YM150 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Caecal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Speech Perception in Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PSA doubling time (PSADT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Action Research Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of participants with asthma combined with idiopathic pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with COPD combined with idiopathic pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with Eosinophilic bronchitis combined with idiopathic pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetics of Doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom of angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-dialysis Recovery Time
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Subjects Who Experience no Nonconvulsive Seizures (NCS) for 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Any Non-serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Duration and severity of fever in patients with influenza and in patients with ARVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with symptoms of ARVI or influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who required antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oxygen saturation after acute exposure to high altitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain levels during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of lumen in target vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Recovery Questionnaire (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reward Valuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effort Valuation/Willingness to Work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Expectancy/Reward Prediction Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial Responsiveness to Reward Attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atherogenic index of plasma (AIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Outcome of Acute Kidney Injury (AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Functional effects of methacholine challenge on small airways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of development of phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation between rSO2 and PbtO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in jumping height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: No hepatitis B virus recurrence after liver transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Protective trough titer of anti hepatitis B antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of infliximab on synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Correlation of predicted dose with actual absorbed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of concordance between thermal image and chest x-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jaw Pain NRS from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jaw Dysfunction NRS from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jaw Pain NRS from baseline to 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jaw Dysfunction NRS from baseline to 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Pregnancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Surface area of subject's scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ability to Reach Target Collection of 5 x 10^6 CD34+ Cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post operative pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial-ankle PWV (baPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of any grade acute or chronic GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Positive Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Number and type of kinases in tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density at Lumbar Spine and Proximal Femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adherence rate to LPV strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Rey Auditory Verbal Learning Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bioelectrical Impedance Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of viral elimination by Day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to viral elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Confirmed HAE Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Who Were HAE Attack-free During the Entire Dosing Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Heel-rise work test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tolerated Maximum Dose (DMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Dose (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Experience Grade 3-5 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Functional
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maintenance of HBV DNA undetectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Pain Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of non-physiologically complex surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of amrubicin and amrubicinol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT/QTc interval effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of amrubicin
Endpoint domain: Adverse events/effects
Primary endpoint: Number of enrolled subjects that remain in study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ADAS-Cog Total Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ADCS-ADL Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite outcome of failure (cup detachments, other instrument used, caesarean section, caput succedaneum, cephalohaematoma, maternal perineal lesions)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in device related anxiety due to battery depletion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in device related anxiety due to device malfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Use of Epidural Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment failure or relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Plasmatic drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Curolox peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cardiovascular and pulmonary disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lung congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: deterioration in heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Behavior Rating Inventory of Executive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavior Assessment System for Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scales of Independent Behavior-Revised
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Variability in plasma concentration of levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Predicted Value Ratio (rNPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spirometry Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HRCT scan of the chest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax of YH4808, amoxicillin, clarithromycin, 14-hydroxyclarithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of YH4808, amoxicillin, clarithromycin, 14-hydroxyclarithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mYPAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC(0 -∞) of HS632 and Xolair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of HS632 and Xolair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of usage hours of positive airway pressure therapy per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in KOOS4
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: longitudinal measure of spleen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute error for blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean absolute error for heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline CAPS-5 at 16 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy in preventing active TB
Endpoint domain: Mortality/survival
Primary endpoint: safety of the regimens
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability to the regimens
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total Nasal Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hematologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MDI use Competence in Clinic
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: MDI use Competence at home
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Successful Rate of Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fMRI activation area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Restore of regular menstrual period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate and extent of exposure of diclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative gastric leak rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients relapsing with stage IIC or greater disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Cured
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With SAE Attributable to HCV Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician Administered PTSD Scale-IV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vital Capacity in liters (VC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Vital Capacity in liters (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume in one second in liters (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1/FVC in percents (FEV1%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak Expiratory Flow in liters (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of the respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alleviation of cachexia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of plasma E2020 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-168) of plasma E2020 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Tissue Microvessel Density (MVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of urinary tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in intensity of withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scale of Prodromal Symptoms - Negative Subscale (SOPS-Neg)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute Haemodynamic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-tumor Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With a Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Death
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in CGI-S (Clinical Global Impression - Severity)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in SRS (Social Responsiveness Scale)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in CDI (Communicative Development Survey) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in PaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of the Submucosal Cushion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: prevention of inpatient induction of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Safety of administration of irradiated autologous tumor cells
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of conversion of delayed tumor hypersensitivity (DTH) tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Mild, Moderate and Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: duration of stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stent occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of lung injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: early virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular function testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: lower-extremity function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mortality of cancer patients
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic accuracy of cervico vaginal β-hCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expired volume in the first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete anatomic resolution of macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Pain Scores (VNRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Indicated Side Effects
Endpoint domain: Adverse events/effects